New scientific data published: DiviTum™ delivers valuable new knowledge in patients with lymphatic disease
Dr N.K Parilova and colleagues at P-A Herzen, Moscow Oncology Research Institute has studied levels of Thymidine Kinase (TK) measured with DiviTum™ in patients with lymphatic diseases. DiviTum™ demonstrated high diagnostic sensitivity for both lymphatic disease and cancer (Non-Hodgkin’s lymphomas). DiviTum™ was compared to traditional biomarkers and DiviTum was the best for identification of patients according to both tumor stage and aggressiveness. The researchers state that the results justifies further measuring of TK when monitoring patients, evaluating the effect of treatments and detecting disease recurrences earlier.
Russian Oncology Journal, Onkologiia (Mosk) 2012; 4: 34-40